MannKind Corporation (MNKD) News
Track canonical SquawkNews coverage tagged to MNKD, MannKind Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
MNKD: Strong early adoption of new products and pipeline progress set the stage for future growth
Three major catalysts—Afrezza pediatric approval, FUROSCIX autoinjector launch, and MNKD-201 phase I-B data—are driving focus on commercial execution and pipeline advancement. Early ReadyFlow adoption and targeted Afrezz
NEWS | Sep 15, 2026, 02:43 PM UTC
L
MNKD: Strong early demand for ReadyFlow and focused pipeline execution set the stage for growth
Three major catalysts—Afrezza pediatric approval, FUROSCIX ReadyFlow launch, and MNKD-201 phase I-B data—are driving focus on commercial execution and pipeline expansion. Early ReadyFlow demand is strong, Afrezza pediatr
NEWS | Sep 15, 2026, 02:18 PM UTC
M
MannKind falls after licensing inhaled GLP-1 program with Rose Pharma
MannKind shares traded lower after the company entered a licensing and collaboration agreement with Rose Pharma to develop an inhaled, rapid-acting GLP-1 receptor agonist using Technosphere technology.
EQUITY | Sep 09, 2026, 03:34 PM UTC
M
MannKind partners with Rose Pharma to develop inhaled GLP-1 treatment
MannKind (MNKD) is partnering with Rose Pharma to develop an inhaled weight-loss treatment using MannKind’s Technosphere platform, targeting the GLP-1 weight-loss market.
EQUITY | Sep 09, 2026, 12:36 PM UTC
L
MannKind, Rose Pharma team up for inhaled GLP-1 therapy
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
EQUITY | Sep 09, 2026, 11:12 AM UTC
L
MannKind and Rose Pharma ink licensing deal for inhaled GLP-1
MannKind and Rose Pharma entered a licensing and collaboration agreement to develop an inhaled rapid-acting, short-duration GLP-1 for weight management.
EQUITY | Sep 09, 2026, 10:30 AM UTC
L
MannKind management to present at upcoming investor conferences
MannKind Corporation management will present at the Cantor Global Healthcare Conference in New York and an additional fireside chat at upcoming investor conferences.
EQUITY | Sep 02, 2026, 12:37 PM UTC
L
MNKD - MannKind to Present at Upcoming Investor Conferences
MNKD - MannKind to Present at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 12:31 PM UTC
M
MannKind filing shows selling stockholders may offer 12.85 million shares
MannKind Corporation says selling stockholders may offer up to 12,853,470 shares, including 2,412,632 warrant shares, in an SEC filing.
REGULATION | Aug 21, 2026, 08:08 PM UTC
H
MNKD Revenue Jumps 43% YoY
MNKD revenue increases 43% year over year
EQUITY | Aug 05, 2026, 08:06 PM UTC
L
MNKD - MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MNKD - MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 05, 2026, 08:01 PM UTC
L
MNKD - MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation o
MNKD - MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
EQUITY | Jul 29, 2026, 10:30 AM UTC
L
MNKD +5.4% premarket after FDA approves Co's single-use autoinjector to treat fluid buildup
MNKD +5.4% premarket after FDA approves Co's single-use autoinjector to treat fluid buildup
REGULATION | Jul 24, 2026, 10:44 AM UTC
L
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for remainder of month: --ELVT expected around 7/23 – Drug rivoceranib + camrelizum
EQUITY | Jul 20, 2026, 05:31 PM UTC
M
MNKD Awarded Grant
MannKind awarded grant to support pediatric trial of Afrezza in youth with newly-diagnosed type 1 diabetes
EQUITY | Jun 23, 2026, 01:01 PM UTC